{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:16:24Z","timestamp":1787030184094,"version":"build-2736575974"},"reference-count":73,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: In 2022, Romania started an RSV immunoprophylaxis program with Palivizumab for infants at high risk: preterm infants born before 35 weeks of pregnancy, infants born with congenital heart defects, and infants with chronic lung disease. We evaluated treatment adherence from August 2022 to March 2024. Method: We monitored the increase in the number of patients enrolled in the program and the number of collaborating neonatologists, family doctors, and pediatricians. Adherence to all doses of Palivizumab in enrolled patients was assessed by telephone interviews. The factors contributing to reduced adherence were identified. Results: Between August 2022 and March 2024, 1903 patients and 233 specialists were enrolled, a steady increase in both cohorts. The percentage of patients that complete their full sequence of doses decreases along with the number of doses (99% for one dose, 73% for two doses, 47% for three doses, 35% for four doses, and 22% for five doses) due to several factors. Conclusions: The program remains highly regarded by both physicians and caregivers, demonstrating its effectiveness as a valuable resource for educating parents and facilitating monoclonal antibody administration as a prevention method for RSV.<\/jats:p>","DOI":"10.3390\/vaccines13020171","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T05:34:32Z","timestamp":1739252072000},"page":"171","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adherence to Palivizumab for Respiratory Syncytial Virus Prophylaxis in Romanian Infants"],"prefix":"10.3390","volume":"13","author":[{"given":"Andreea","family":"Calomfirescu-Avramescu","sequence":"first","affiliation":[{"name":"Filantropia Clinical Hospital, 011171 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian Ioan","family":"Toma","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Titu Maiorescu University, 040441 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Mehedin\u021bu","sequence":"additional","affiliation":[{"name":"Filantropia Clinical Hospital, 011171 Bucharest, Romania"},{"name":"Obstetrics-Gynecology and Neonatology Department, Carol Davila University of Medicine and Pharmacy, 020956 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"N\u0103stase","sequence":"additional","affiliation":[{"name":"Obstetrics-Gynecology and Neonatology Department, Carol Davila University of Medicine and Pharmacy, 020956 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5969-9205","authenticated-orcid":false,"given":"Vlad","family":"Dima","sequence":"additional","affiliation":[{"name":"Filantropia Clinical Hospital, 011171 Bucharest, Romania"},{"name":"Obstetrics-Gynecology and Neonatology Department, Carol Davila University of Medicine and Pharmacy, 020956 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children","volume":"360","author":"Hall","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/ppul.23570","article-title":"Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysis","volume":"52","author":"Stein","year":"2017","journal-title":"Pediatr. Pulmonol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"ref_5","first-page":"46","article-title":"A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis","volume":"16","author":"Frogel","year":"2010","journal-title":"J. Manag. Care Pharm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/jp.2016.113","article-title":"Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants","volume":"36","author":"McLaurin","year":"2016","journal-title":"J. Perinatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1017\/S0950268814001393","article-title":"Influence of age, severity of infection, and co-infection on the duration of respiratory syncytial virus (RSV) shedding","volume":"143","author":"Munywoki","year":"2015","journal-title":"Epidemiol. Infect."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.coviro.2017.03.015","article-title":"Ongoing developments in RSV prophylaxis: A clinician\u2019s analysis","volume":"24","author":"Rezaee","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.15585\/mmwr.mm6702a4","article-title":"Respiratory syncytial virus seasonality\u2014United States, 2014\u20132017","volume":"67","author":"Rose","year":"2018","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/infdis\/jiy056","article-title":"Respiratory syncytial virus seasonality: A global overview","volume":"217","author":"Sly","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.15585\/mmwr.mm7029a1","article-title":"Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic\u2014United States, 2020\u20132021","volume":"70","author":"Olsen","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e2021051462","DOI":"10.1542\/peds.2021-051462","article-title":"Acute Respiratory Illnesses in Children in the SARS-CoV-2 Pandemic: Prospective Multicenter Study","volume":"148","author":"Haddadin","year":"2021","journal-title":"Pediatrics"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/cid\/ciaa1328","article-title":"Impact of social distancing and travel restrictions on non-coronavirus disease 2019 (Non-COVID-19) respiratory hospital admissions in young children in rural Alaska","volume":"72","author":"Nolen","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/cid\/ciaa1475","article-title":"Impact of coronavirus disease 2019 public health measures on detections of influenza and respiratory syncytial virus in children during the 2020 Australian winter","volume":"72","author":"Yeoh","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1542\/peds.2013-0303","article-title":"Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age","volume":"132","author":"Hall","year":"2013","journal-title":"Pediatrics"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s10096-018-3256-0","article-title":"Respiratory syncytial virus prophylaxis in cystic fibrosis: The Canadian registry of palivizumab data (2005\u20132016)","volume":"37","author":"Mitchell","year":"2018","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/INF.0000000000000918","article-title":"Respiratory syncytial virus preterm (32\u201336 completed weeks of gestation) risk estimation measure for RSV hospitalization in Ireland: A prospective study","volume":"35","author":"Murphy","year":"2016","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40121-016-0142-x","article-title":"Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among infants with congenital heart disease","volume":"6","author":"Checchia","year":"2017","journal-title":"Infect. Dis. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/ppul.24137","article-title":"Increased severity of respiratory syncytial virus airway infection due to passive smoke exposure","volume":"53","author":"Maedel","year":"2018","journal-title":"Pediatr. Pulmonol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/cid\/ciy1071","article-title":"Impaired transplacental transfer of respiratory syncytial virus-neutralizing antibodies in human immunodeficiency virus-infected versus-uninfected pregnant women","volume":"69","author":"Jallow","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e20180225","DOI":"10.1542\/peds.2018-0225","article-title":"Down syndrome and the risk of severe RSV infection: A meta-analysis","volume":"142","author":"Beckhaus","year":"2018","journal-title":"Pediatrics"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"020416","DOI":"10.7189\/jogh.05.020416","article-title":"Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: Systematic review and meta-analysis","volume":"5","author":"Shi","year":"2015","journal-title":"J. Glob. Health"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/14767050903194438","article-title":"Respiratory syncytial virus risk factors in late preterm infants","volume":"22","author":"Lanari","year":"2009","journal-title":"J. Matern. Neonatal Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/INF.0b013e3181710990","article-title":"FLIP-2 Study: Risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks","volume":"27","year":"2008","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/INF.0000000000001377","article-title":"Burden of severe respiratory syncytial virus disease among 33\u201335 weeks\u2019 gestational age infants born during multiple respiratory syncytial virus seasons","volume":"36","author":"Anderson","year":"2017","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/ppul.23960","article-title":"Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants","volume":"53","author":"Blanken","year":"2018","journal-title":"Pediatr. Pulmonol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/PHMT.S59572","article-title":"Respiratory syncytial virus-related hospitalization in premature infants without bronchopulmonary dysplasia: Subgroup efficacy analysis of the IMpact-RSV trial by gestational age group","volume":"5","author":"Waycaster","year":"2014","journal-title":"Pediatr. Health Med. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/INF.0000000000000219","article-title":"Respiratory syncytial virus disease in preterm infants in the U.S. born at 32\u201335 weeks gestation not receiving immunoprophylaxis","volume":"33","author":"Ambrose","year":"2014","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Stra\u0148\u00e1k, Z., Saliba, E., Kosma, P., Posfay-Barbe, K., Yunis, K., Farstad, T., Unnebrink, K., van Wyk, J., Wegzyn, C., and Notario, G. (2016). Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 weeks gestational age: A large multinational study (PONI). PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0157446"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1053\/rmed.2002.1296","article-title":"Respiratory syncytial virus prophylaxis\u2014The story so far","volume":"96","author":"Simoes","year":"2002","journal-title":"Respir. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5152\/TurkPediatriArs.2018.6939","article-title":"Respiratory syncytial vir\u00fcs infections in neonates and infants","volume":"53","author":"Perk","year":"2018","journal-title":"Turk. Arch. Pediatr.\/T\u00fcrk. Pediatr. Ar\u015fivi"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3389\/fimmu.2014.00466","article-title":"Immunity to RSV in early-life","volume":"5","author":"Lambert","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1128\/CMR.00090-16","article-title":"The human immune response to respiratory syncytial virus infection","volume":"30","author":"Russell","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jpeds.2008.07.053","article-title":"Seasonal variation of maternally derived respiratory syncytial virus antibodies and association with infant hospitalizations for respiratory syncytial virus","volume":"154","author":"Stensballe","year":"2009","journal-title":"J. Pediatr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/modpathol.3800725","article-title":"The histopathology of fatal untreated human respiratory syncytial virus infection","volume":"20","author":"Johnson","year":"2007","journal-title":"Mod. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jpeds.2009.04.063","article-title":"Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: A systematic review","volume":"155","author":"Ralston","year":"2009","journal-title":"J. Pediatr."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Murray, J., Bottle, A., Sharland, M., Modi, N., Aylin, P., Majeed, A., Saxena, S., and on behalf of the Medicines for Neonates Investigator Group (2014). Risk factors for hospital admission with RSV bronchiolitis in England: A population-based birth cohort study. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0089186"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(19)30721-4","article-title":"Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: The PERCH multi-country case-control study","volume":"394","author":"Baggett","year":"2019","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5005\/jp-journals-11002-0073","article-title":"Respiratory Syncytial Virus Infections in Neonates: A Persisting Problem","volume":"2","author":"Singh","year":"2023","journal-title":"Newborn"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"R107","DOI":"10.1186\/cc4984","article-title":"Extrapulmonary manifestations of severe respiratory syncytial virus infection\u2014A systematic review","volume":"10","author":"Eisenhut","year":"2006","journal-title":"Crit. Care"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1097\/INF.0b013e31829561dd","article-title":"Potential for palivizumab interference with commercially available antibody-antigen based respiratory syncytial virus diagnostic assays","volume":"32","author":"Deming","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1128\/JCM.01816-15","article-title":"Diagnostic Accuracy of Rapid Antigen Detection Tests for Respiratory Syncytial Virus Infection: Systematic Review and Meta-analysis","volume":"53","author":"Chartrand","year":"2015","journal-title":"J. Clin. Microbiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jcv.2018.08.009","article-title":"Respiratory syncytial virus testing capabilities and practices among National Respiratory and Enteric Virus Surveillance System Laboratories, United States, 2016","volume":"107","author":"Allen","year":"2018","journal-title":"J. Clin. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/PAT.0000000000000240","article-title":"Molecular diagnosis of respiratory viruses","volume":"47","author":"Somerville","year":"2015","journal-title":"Pathology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy381","article-title":"A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the Infectious Diseases Society of America and the American Society for Microbiology","volume":"67","author":"Miller","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_46","unstructured":"Jain, H., Schweitzer, J.W., and Justice, N.A. (2024). Respiratory Syncytial Virus Infection in Children. StatPearls, StatPearls Publishing."},{"key":"ref_47","first-page":"CD000181","article-title":"Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children","volume":"18","author":"Ventre","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2165\/00003495-199754060-00006","article-title":"Prevention and treatment recommendations for respiratory syncytial virus infection. Background and clinical experience 40 years after discovery","volume":"54","author":"Ottolini","year":"1997","journal-title":"Drugs"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2010-08-263400","article-title":"Management of RSV infections in adult recipients of hematopoietic stem cell transplantation","volume":"117","author":"Shah","year":"2011","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/cid\/cis844","article-title":"Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus","volume":"56","author":"Hirsch","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00006454-200205000-00037","article-title":"Safety issues related to the administration of ribavirin","volume":"21","author":"Krilov","year":"2002","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e13511","DOI":"10.1111\/ctr.13511","article-title":"RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Manuel","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"BELRSM Kimberlin, D.W. (2021). Respiratory Syncytial Virus. Red Book: 2021\u20132024 Report of the Committee on Infectious Diseases, American Academy of Pediatrics. [32nd ed.].","DOI":"10.1542\/9781610027373"},{"key":"ref_54","unstructured":"(2015). Overview: Bronchiolitis in Children: Diagnosis and Management, Guidance NICE; National Institute for Health and Care Excellence."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1128\/microbiolspec.AID-0014-2014","article-title":"Prevention of respiratory syncytial virus infection: From vaccine to antibody","volume":"2","author":"Huang","year":"2014","journal-title":"Microbiol. Spectr."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics, Committee on Infect\u0131ous D\u0131seases and Bronchiolitis Gu\u0131del\u0131nes Comm\u0131ttee (2014). Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics, 134, 415\u2013420.","DOI":"10.1542\/peds.2014-2783"},{"key":"ref_57","first-page":"416","article-title":"Actualities in neonatal endocrine and metabolic screening","volume":"17","author":"Dima","year":"2021","journal-title":"Acta Endocrinol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Bohil\u021bea, R.E., Cioca, A.M., Dima, V., Ducu, I., Grigoriu, C., Varlas, V., and Furtunescu, F. (2021). Expectant Management of PPROM Improves Neonatal Outcome-A Retrospective Study of 562 Patients. J. Clin. Med., 11.","DOI":"10.3390\/jcm11010214"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose Nirsevimab for prevention of RSV in preterm infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for Prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_61","unstructured":"(2023, August 31). FDA Approves New Drug to Prevent RSV in Babies and Toddlers\/FDA, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-prevent-rsv-babies-and-toddlers."},{"key":"ref_62","unstructured":"Synagis (Palivizumab) (2008). Full Prescribing Information, MedImmune LLC. Available online: http:\/\/www.medimmune.com\/pdf\/products\/synagis_pi.pdf."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Gambadauro, A., Galletta, F., Li Pomi, A., Manti, S., and Piedimonte, G. (2024). Immune Response to Respiratory Viral Infections. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25116178"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Manti, S., Gambadauro, A., Galletta, F., Ruggeri, P., and Piedimonte, G. (2024). Update on the Role of \u03b22AR and TRPV1 in Respiratory Diseases. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251910234"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/tid.12510","article-title":"Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: A survey of institutions in the Midwestern Respiratory Virus Collaborative","volume":"18","author":"Beaird","year":"2016","journal-title":"Transpl. Infect. Dis."},{"key":"ref_66","first-page":"CD006602","article-title":"Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children","volume":"2013","author":"Andabaka","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_67","unstructured":"(2023). Isolation Precautions: Guidelines Library."},{"key":"ref_68","unstructured":"HAI CDC (2023). Guide to Infection Prevention for Outpatient Settings: Minimum Expectations for Safe Care."},{"key":"ref_69","first-page":"1","article-title":"Guidelines for preventing health-care-associated pneumonia, 2003: Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee","volume":"53","author":"Tablan","year":"2004","journal-title":"MMWR Recomm. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1017\/S1047951124024946","article-title":"Behavioural interventions to increase adherence to palivizumab prophylaxis in children with CHD","volume":"34","author":"Erolu","year":"2024","journal-title":"Cardiol. Young"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s10900-014-9877-z","article-title":"Palivizumab compliance by infants in Puerto Rico during the 2009\u20132010 respiratory syncytial virus season","volume":"39","year":"2014","journal-title":"J. Community Health"},{"key":"ref_72","first-page":"338","article-title":"Improving Palivizumab Compliance rough a Pharmacist-Managed RSV Prevention Clinic","volume":"22","author":"Chow","year":"2017","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/01.pec.0000278406.75815.d3","article-title":"Evaluation of compliance with palivizumab recommendations in a multicenter study of young children presenting to the emergency department with bronchiolitis","volume":"23","author":"Mansbach","year":"2007","journal-title":"Pediatr. Emerg. Care"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/2\/171\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:30:44Z","timestamp":1760027444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/2\/171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":73,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["vaccines13020171"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13020171","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]}}}